For the quarter ending 2025-09-30, NKTR had -$1,956K decrease in cash & cash equivalents over the period. -$48,875K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Revenue | 33,425 | - |
| Rezpegaldesleukin | 37,888 | - |
| NKTRZero One Six Five | 8,931 | - |
| NKTRTwo Five Five | 5,034 | - |
| Discovery Research And Other Programs | 1,018 | - |
| Clinical development, contract manufacturing and other third party costs | 52,871 | - |
| Employee costs | 33,782 | - |
| Facilities costs | 9,378 | - |
| Other operating costs | 37,881 | - |
| Other segment expenses | 11,950 | - |
| Total operating costs and expenses | 145,862 | - |
| Loss from operations | -112,437 | - |
| Non-cash interest expense on liabilities related to the sales of future royalties | 6,047 | - |
| Interest income | 7,662 | - |
| Other income (expense), net | 405 | - |
| Total non-operating income (expense), net | -8,348 | - |
| Loss before provision (benefit) for income taxes and equity method investment | -120,785 | - |
| Provision (benefit) for income taxes | -169 | - |
| Loss before equity method investment | -120,616 | - |
| Loss from equity method investment | -534 | - |
| Net loss | -35,522 | -92,475 |
| Non-cash royalty revenue related to the sales of future royalties | 11,490 | 21,635 |
| Non-cash interest expense on liabilities related to the sales of future royalties | 6,047 | 10,368 |
| Loss from equity method investment | -534 | -6,847 |
| Stock-based compensation | 3,072 | 7,384 |
| Depreciation and amortization expense | 196 | 640 |
| Impairment of right-of-use assets and property and equipment | 0 | 0 |
| Provision for net realizable value of inventory | 0 | 0 |
| Amortization of premiums (discounts), net | -1,433 | -2,193 |
| Accounts receivable | 0 | 0 |
| Inventory | 0 | 0 |
| Operating leases, net | 3,827 | 5,580 |
| Other assets | 618 | 4,973 |
| Accounts payable | 1,282 | 2,886 |
| Accrued expenses | -7,002 | 3,940 |
| Net cash used in operating activities | -48,761 | -94,791 |
| Purchases of investments | 149,558 | 43,852 |
| Maturities of investments | 54,799 | 137,892 |
| Purchases of property and equipment | 114 | 39 |
| Payment of transaction costs and working capital adjustment from the sale of the huntsville manufacturing facility | 0 | 697 |
| Net cash provided by (used in) investing activities | -94,873 | 93,304 |
| Proceeds from shares issued under equity compensation plans and other | 238 | 218 |
| Proceeds from offering, net-Two Thousand Twenty Five Secondary Public Offering | 108,100 | - |
| Proceeds from offering, net-At The Market Offering | 34,489 | - |
| Payments of offering costs associated with issuance of common stock | 1,150 | - |
| Proceeds from issuance of pre-funded warrant | 0 | 0 |
| Proceeds from sale of future royalties | 0 | 0 |
| Repurchase of common stock from bristol-myers squibb | 0 | 0 |
| Net cash provided by financing activities | 141,677 | 218 |
| Effect of foreign exchange rates on cash and cash equivalents | 1 | 5 |
| Net decrease in cash and cash equivalents | -1,956 | -1,264 |
| Cash and cash equivalents at beginning of period | 44,252 | - |
| Cash and cash equivalents at end of period | 41,032 | - |
NEKTAR THERAPEUTICS (NKTR)
NEKTAR THERAPEUTICS (NKTR)